Nusafe Spółka z Ograniczoną Odpowiedzialnością (KRS 0000620149, NIP 5213736472) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Nusafe operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since May 25, 2016.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Nusafe
Identity
- Name
- Nusafe Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- May 25, 2016
- Registry status as of
- November 21, 2025
- Latest entry
- April 14, 2025
- Founding act
- 22.04.2016 R., NOTARIUSZ ROBERT KUSKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 2697/2016
Articles of association history (3)
- April 22, 2016: 22.04.2016 R., NOTARIUSZ ROBERT KUSKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 2697/2016
- June 15, 2016: 15.06.2016 R., REP. A NR 4047/2016, NOTARIUSZ ROBERT KUSKOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA § 1 UST. 2 I UST. 3, § 3 UST. 1, W § 3 DODANO UST. 6
- April 10, 2019: AKT NOTARIALNY Z DNIA 10.04.2019 R. REP. A NR 4570/2019 SPORZĄDZONY PRZED NOTARIUSZEM ARTUREM STANISŁAWEM KOZAKIEM PROWADZĄCYM KANCELARIĘ NOTARIALNĄ W WARSZAWIE, AL. JANA PAWŁA II 61 LOK. 4, 01-031 WARSZAWA ZMIANIE PODLEGAŁY: § 8, § 9 UST. 6), § 9 UST.7) UMOWY SPÓŁKI SKREŚLONO: § 10 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- UL. POLECZKI, 35, 02-822, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-90393-85824-VGCUA-28
- Coordinates
- 52.2298, 21.0117approx.
Operational status - Nusafe
Founded
May 25, 2016
10 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
13.1 K PLN
262 shares total
Shareholders
1
shareholder
Board
1 person
Registry entries
25
latest: April 14, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Board and connected people - Nusafe
People holding roles at Nusafe according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Katarzyna Anna KuśmierzBoard member, Supervisory board member
- Rafał Tadeusz DalewskiBoard member, Majority shareholder
- Robert Krzysztof JaremaBoard member, Majority shareholder
- Francis Patrick OstronicSupervisory board member
- Tomasz Edward PonińskiSupervisory board member
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Nusafe.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.